“This could have been a challenging case since it involved a large renal tumour fed by small, low flow, tortuous vessels. We were able to use our standard embolic microcatheter to deliver GPX in a highly controlled fashion. Since we were not worried about catheter entrapment, we could take our time and ensure that we occluded all targeted vessels completely. GPX flowed distally very well, completely filling the targeted region,” said Martin Krauss, head of Interventional Radiology, Christchurch Hospital, Christchurch, New Zealand. “Based on our case experiences, GPX is a great product for effectively filling distal vasculature.”
Fluidx Medical states that the GPX embolic device is an innovative embolic designed for simple preparation and controlled delivery. The device is packaged ready to use in a syringe, can be prepped tableside by the clinician in about 30 seconds, and may be delivered through standard microcatheters (no complex mixing systems or special delivery catheters are necessary), the company adds.
A press release details that GPX technology is a low viscosity, aqueous-based solution in a syringe that solidifies into a durable embolus upon delivery without polymerisation or dimethyl-sulfoxide (DMSO) precipitation, a press release explains. According to Fluidx Medical, GPX is designed to occlude blood vessels independent of a patient’s coagulation situation.
“Treating a tumour with multiple feeding vessels in a controlled, thorough manner without risk of catheter entrapment can improve patient care and minimise the need for follow-on procedures,” said Libble Ginster, CEO of Fluidx Medical Technology. “GPX demonstrates improved control and precision. GPX does not require 20+ minutes of preparation time or the clinician to use a special catheter system. The simplicity of GPX preparation makes real-time clinical decision-making possible. We continue to be excited about the GPX portfolio and its future in advancing cancer care.”
The GPX embolic device is under development and does not have marketing clearance or approval in any market at this time, the company advises. It is for investigational use (in New Zealand) only.